ℹ️ Observational Association Only Evidence
Depression risk is documented across corticosteroids, anticonvulsants, opioids, hormonal contraceptives, PPIs, stimulants, benzodiazepines, isotretinoin, levodopa, and GLP-1 agonists. Disentangling drug effect from underlying condition remains a persistent diagnostic challenge.
Clinical Considerations
- Corticosteroids carry the strongest signal, with depression, anxiety, and insomnia appearing within 5 days at higher doses or with prolonged use.
- One analysis suggested 14% of depression cases could be averted by discontinuing PPIs, though confounding by indication limits interpretation.
- Levodopa worsens depression at higher doses in Parkinson’s patients, while dopamine agonists showed no comparable signal.
- Adolescents ages 15 to 19, progestin-only users, and non-oral hormonal contraceptive users showed modestly elevated depression risk in pooled data.
Practice Applications
- Recognize new mood symptoms within weeks of starting corticosteroids, levodopa, or hormonal contraceptives.
- Interpret depression onset against confounding by indication before attributing causality to the medication.
- Monitor opioid recipients past the 30-day mark, when depression incidence rises.
- Avoid abrupt PPI or benzodiazepine discontinuation; taper to prevent rebound and withdrawal-driven mood symptoms.
Related Reading
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS